What should you know about immunotherapy and lung cancer?

Some immune medicines block signals that shield cancer cells from immune attack. They may be considered alone or alongside chemotherapy, surgery, or radiotherapy. The plan differs for cancer contained in the chest, cancer that has returned, and cancer that has spread to another part of the body.

The team reviews the lung cancer type, scans, biopsy information, genomic tumour profiling when relevant, earlier treatment, and other illnesses. During treatment, symptoms, blood tests, and imaging help guide decisions about continuing, changing, or pausing the plan.

Tell the oncology team about autoimmune conditions, transplant history, lung disease, medicines, and supplements. Ask how treatment is administered, what monitoring is planned, and how to reach the team between visits. Report changes early, even if they seem unrelated to the lungs.

Immune-related inflammation can involve the lungs, skin, bowel, liver, kidneys, or hormone glands. Early assessment helps distinguish a treatment effect from infection, cancer symptoms, or another cause.

Call the treatment team promptly for new breathlessness, worsening cough, chest pain, persistent diarrhoea, severe rash, yellowing of the skin, reduced urine, or unusual weakness. Emergency care is appropriate for severe breathing difficulty, fainting, confusion, or sudden weakness or speech trouble.

What type and stage of lung cancer do I have? Are tumour or genomic findings relevant to immunotherapy? Will it be combined with chemotherapy, surgery, or radiotherapy? Which symptoms need same-day advice, and what number should I call?